Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells 7,370 Shares of Stock

Chimerix, Inc. (NASDAQ:CMRX) CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Chimerix Stock Performance

CMRX opened at $4.38 on Friday. The company has a fifty day moving average of $3.53 and a two-hundred day moving average of $1.82. The stock has a market capitalization of $393.94 million, a price-to-earnings ratio of -4.66 and a beta of 0.35. Chimerix, Inc. has a fifty-two week low of $0.75 and a fifty-two week high of $4.65.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently modified their holdings of the business. Bender Robert & Associates acquired a new position in Chimerix in the 4th quarter worth about $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix in the fourth quarter valued at approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the 4th quarter worth approximately $101,000. Finally, Stoneridge Investment Partners LLC lifted its position in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 8,134 shares in the last quarter. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CMRX shares. Wedbush reissued an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Chimerix in a report on Monday, December 30th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.